Cargando…
Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies
High grade gliomas are malignant brain tumors that arise in the central nervous system, in patients of all ages. Currently, the standard of care, entailing surgery and chemo radiation, exhibits a survival rate of 14-17 months. Thus, there is an urgent need to develop new therapeutic strategies for t...
Autores principales: | Garcia-Fabiani, Maria B., Haase, Santiago, Comba, Andrea, Carney, Stephen, McClellan, Brandon, Banerjee, Kaushik, Alghamri, Mahmoud S., Syed, Faisal, Kadiyala, Padma, Nunez, Felipe J., Candolfi, Marianela, Asad, Antonela, Gonzalez, Nazareno, Aikins, Marisa E., Schwendeman, Anna, Moon, James J., Lowenstein, Pedro R., Castro, Maria G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217836/ https://www.ncbi.nlm.nih.gov/pubmed/34168976 http://dx.doi.org/10.3389/fonc.2021.631037 |
Ejemplares similares
-
Current Approaches for Glioma Gene Therapy and Virotherapy
por: Banerjee, Kaushik, et al.
Publicado: (2021) -
Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment
por: Franson, Andrea, et al.
Publicado: (2022) -
Impact of epigenetic reprogramming on antitumor immune responses in glioma
por: McClellan, Brandon L., et al.
Publicado: (2023) -
H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Pediatric High-Grade Gliomas
por: Garcia-Fabiani, Maria B., et al.
Publicado: (2023) -
Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments
por: Alghamri, Mahmoud S., et al.
Publicado: (2021)